CRM is collaborating with the Global Antibiotic Research & Development Partnership (GARDP) to advance Malaysia’s efforts in addressing antimicrobial resistance (AMR) and improving access to essential antibiotics.
CRM is collaborating with the Global Antibiotic Research & Development Partnership (GARDP) to advance Malaysia’s efforts in addressing antimicrobial resistance (AMR) and improving access to essential antibiotics.
The clinical research industry is a booming one, with a global value standing at over US$480bil (RM368bil) last year, and it is projected to grow 6.5% annually.
We are thrilled to shine the spotlight on some of the achievements noted in several of Novo Nordisk (NN) global studies conducted, that have Malaysian sites demonstrating outstanding clinical trial performance throughout 2024.
Malaysia has received five new First-in-Human (FIH) trials through Clinical Research Malaysia (CRM), marking the highest number of FIH clinical research ever achieved, said Health Minister Datuk Seri Dr Dzulkefly Ahmad.
The clinical research industry is a booming one, with a global value standing at over US$480bil (RM368bil) last year, and it is projected to grow 6.5% annually.
It all started with a single file cabinet at the Sarawak General Hospital (SGH) for Dr Chew Lee Ping.
WHEN Syed Johari Syed Jamaludin found out he had idiopathic pulmonary fibrosis (IPF), he knew he would die soon
The question was how soon?
Sarawak General Hospital (SGH), together with its Clinical Research Centre (CRC) celebrated a series of significant milestones in early phase clinical research, positioning itself as a key player in the global First-in-Human (FIH) clinical trial landscape.
Professor Dr Serena Nik-Zainal, a Malaysian Scientist who is based in the United Kingdom has received the prestigious ESMO Award for Translational Research during the Opening Ceremony at the European Society of Medical Oncology (ESMO) Congress 2024
Clinical Research Malaysia is expanding in its business as we experience an increased volume of trials in the country. The business expansion has become inevitable due to the growth of sponsored research in the region and with Malaysia seen as a favorable site for multi-regional clinical trials.